February 24, 2020/ The French drugmaker said it’s creating the world’s second largest active pharmaceutical ingredients (API) manufacturer by spinning out its six current sites into a standalone company: Brindisi (Italy)……
Feb.23, 2020 / Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ? (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being taken after ……
January 23, 2020 / The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved the expanded use of STELARA? (ustekinumab) for the treatment of paediatric patie……
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved a new indication for Revlimid (lenalidomide), in combination with rituximab (anti-……
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq? (atezolizumab) in combination with chemotherapy (Abraxane? [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the init……
Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President and Representative Director: Gyo Sagara;“ONO”) announced today that it has launched Coralan? (generic name: ivabradine hydrochloride)Tablet 2.5mg, 5mg and 7.5mg (“Cor……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
